Lucitanib plus toripalimab showed encouraging antitumor activity with manageable safety in heavily pretreated advanced solid tumors, supporting further randomized evaluation, particularly in NPC and EC. Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2400087935.

Its efficacy was intermediate between methotrexate and the selective NTRK2 inhibitor ana-12. Mechanistically, Lucitanib targeted the NTRK2-AKT-MMP9 axis while preserving immune effector functions. These findings establish NTRK2 as a viable therapeutic target in gliomas and highlight Lucitanib as a novel multi-mechanistic inhibitor with balanced efficacy and favorable pharmacokinetic properties, supporting its further development for clinical translation in NTRK2-overexpressing gliomas.

P2, N=74, Active, not recruiting, GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Recruiting --> Active, not recruiting

P1/2, N=180, Completed, Sun Yat-sen University Cancer Center; Haihe Biopharma Co.,Ltd.

Current clinical trials, including those evaluating FGFR inhibitors like erdafitinib, lucitanib, and dovitinib, have demonstrated mixed outcomes, underscoring the complexity of FGFR signaling in breast cancer. In conclusion, targeting FGFR signaling in ER+ breast cancer presents both challenges and opportunities. A deeper understanding of the molecular mechanisms and resistance pathways is crucial for the successful integration of FGFR inhibitors into clinical practice, aiming to improve outcomes for patients with endocrine-resistant breast cancer.

P2, N=100, Recruiting, GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2027

P2, N=15, Completed, Grupo Espanol de Investigacion en Sarcomas | Recruiting --> Completed | N=39 --> 15

P2, N=46, Active, not recruiting, National Cancer Institute, Naples | Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Nov 2021 --> Nov 2024

P2, N=28, Recruiting, Sun Yat-sen University | Unknown status --> Recruiting | N=43 --> 28 | Trial completion date: Jul 2020 --> Jul 2023 | Trial primary completion date: Jul 2020 --> Feb 2023

In real-world clinical setting, TAS-102 showed consistent clinical efficacy and manageable safety with previous prospective clinical studies. Compared with monotherapy and TAS-102 plus ICIs, TAS-102 plus bevacizumab demonstrated better clinical efficacy for metastatic colorectal cancer.

VAF of the majority of the ctDNA mutations increased at the time of disease progression, and VAF of BRAF increased markedly. Reduction in ctDNA burden as estimated by sum (VAF) could be used to predict treatment outcome of regorafenib.